Please login to the form below

Not currently logged in
Email:
Password:

voclosporin

This page shows the latest voclosporin news and features for those working in and with pharma, biotech and healthcare.

Lupus trial hailed as a success despite patient deaths

Lupus trial hailed as a success despite patient deaths

Phase IIb trial of Aurinia Pharmaceuticals’ voclosporin met its objective. A medical charity representing patients with lupus erythematosus has welcomed the results of a study showing the efficacy of a new ... The phase IIb trial of Aurinia

Latest news

  • Scratching the surface

    The ESSENCE and SPIRIT trials have been completed for Isotechnika's voclosporin, a calcineurin inhibitor and oral immunosuppressant. ... The likelihood of voclosporin gaining approval is 58 per cent, according to inThought analysts.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Bayer veteran joins Aurinia as CEO Bayer veteran joins Aurinia as CEO

    Aurinia is well positioned to bring voclosporin forward as an important new treatment for lupus nephritis,” he said. ... companies. “He is exceptionally qualified to help us build our voclosporin franchise and sharpen our execution.".

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics